海湾合作委员会国家血液透析患者中糖尿病的患病率、治疗、控制及结局
该研究基于2012—2018年海湾合作委员会(GCC)国家DOPPS前瞻性队列中2274例成人血液透析患者,首次描述各国糖尿病患病率、相关治疗与结局及HbA1c与死亡的关联。糖尿病患者较非糖尿病患者粗死亡率更高(15.6 vs 6.2/100患者年),校正后死亡风险仍升高(HR=1.72,95%CI 1.23-2.39);糖尿病患者中HbA1c 6.5%~7.5%时死亡率最低,HbA1c>9%时死亡风险升高(HR=2.13,95%CI 1.10-4.10)。
要点
- GCC国家血液透析患者糖尿病患病率为45%~74%。
- 糖尿病患者粗死亡率为15.6/100患者年,非糖尿病患者为6.2/100患者年。
- 糖尿病患者校正后死亡风险较非糖尿病患者升高(HR=1.72,95%CI 1.23-2.39)。
核心结论
- GCC国家血液透析患者中糖尿病患病率高、合并症负担重且死亡率高,尽管平均年龄相对年轻;需要从初级、二级和三级层面制定综合策略改善糖尿病护理与结局。
研究设计与样本
- 分析2012—2018年海湾合作委员会(GCC)国家DOPPS前瞻性研究数据,纳入2274例≥18岁血液透析患者。
- 计算描述性统计,并按有无糖尿病及糖尿病患者HbA1c水平,采用逐步校正混杂因素的Cox回归分析全因死亡率。
主要发现
- GCC国家血液透析患者糖尿病患病率范围为45%~74%。
- 糖尿病患者较非糖尿病患者年龄大13岁(59.9 vs 46.7岁),BMI更高,透析中位年数更短(1.5 vs 3.0年),合并症负担更高。
- 糖尿病患者中,各国胰岛素使用比例为26%~50%,口服降糖药使用比例不一(2%~32%),HbA1c中位水平为6.1%~7.5%。
- 糖尿病患者较非糖尿病患者粗死亡率更高(15.6 vs 6.2/100患者年,平均随访1.3年),校正后死亡风险升高(HR=1.72,95%CI 1.23-2.39)。
- 糖尿病患者中,HbA1c 6.5%~7.5%时死亡率最低,HbA1c>9%时死亡风险升高(HR=2.13,95%CI 1.10-4.10)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Diabetes mellitus (DM) is a leading cause of end-stage kidney disease (ESKD). We provide the first description of DM prevalence, related outcomes, and the hemoglobin A1c (HbA1c)/mortality relationship in national hemodialysis (HD) patient samples across the Gulf Cooperation Council (GCC) countries. METHODS: We analyzed data from the prospective Dialysis Outcomes and Practice Patterns Study (DOPPS) in the GCC (2012-2018, N = 2274 HD patients ≥18 years old). Descriptive statistics were calculated, and all-cause mortality was analyzed for patients with DM versus without DM and by HbA1c levels in patients with DM by Cox regression with progressive confounder adjustments. RESULTS: DM in the GCC ranged from 45% to 74% in patients with HD by country. Patients with DM were 13 years older (59.9 vs. 46.7 years) and had greater body mass index (BMI), shorter median years on dialysis (1.5 vs. 3.0 years), and higher comorbidity burden. In patients with DM, insulin use was 26% to 50% across countries, with variable oral antidiabetic drug use (2%-32%); median HbA1c levels were 6.1% to 7.5% across countries. Patients with DM (vs. without DM) had higher crude death rates (15.6 vs. 6.2 deaths per 100 patient-years, mean follow-up 1.3 years) and adjusted mortality (hazard ratio [HR] = 1.72 [95% CI 1.23-2.39]). In patients with DM, mortality was lowest at HbA1c 6.5% to 7.5%, with mortality particularly elevated at high HbA1c >9% (HR = 2.13 [95% CI 1.10-4.10]). CONCLUSION: Patients with DM in the GCC have high comorbidity burden and mortality rates despite a relatively young mean age. In GCC countries, a holistic strategy for improving diabetes care and outcomes for HD patients is needed at the primary, secondary, and tertiary levels.
引用
- Al-Ghamdi SMG, Bieber B, AlRukhaimi M, et al. Diabetes Prevalence, Treatment, Control, and Outcomes Among Hemodialysis Patients in the Gulf Cooperation Council Countries. Kidney Int Rep. 2022. PMID: 35570992. doi:10.1016/j.ekir.2022.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。